Contents

Vascular InfectionEdit

Vascular infection encompasses a spectrum of infectious processes involving the arterial and venous systems, including native vessels, prosthetic vascular material, and intravascular devices. These infections are a convergence of infectious disease and vascular surgery, demanding swift recognition, decisive source control, and targeted antimicrobial therapy. They carry substantial risks of sepsis, organ dysfunction, limb loss, and death if not promptly addressed. In modern practice, management hinges on accurate diagnosis, multidisciplinary coordination, and prudent use of antibiotics coupled with timely surgical intervention when needed.

Although relatively uncommon compared with other infectious diseases, vascular infections are disproportionately serious because they often involve prosthetic material or compromised vessels. Their incidence has risen in step with vascular interventions, implanted devices, and prolonged survival of patients with atherothrombotic disease or immunosuppression. Across populations, risk factors include preexisting vascular disease, diabetes mellitus, intravenous drug use, prior vascular surgery, indwelling venous or arterial catheters, and immune suppression. The clinical course ranges from focal, localized infection to fulminant sepsis, and outcomes improve markedly when diagnosis and treatment occur early.

Terminology and scope

Vascular infection can affect native arteries and veins or involve prosthetic material such as vascular grafts, stents, or endovascular devices. Infected prosthetic vascular grafts are a major subset and pose particular challenges because biofilm formation on artificial material can shield organisms from host defenses and antibiotics. Infected aneurysms, sometimes referred to as mycotic aneurysms, arise when infection weakens the vessel wall, creating a risk of rupture. Intravascular devices, including central venous catheters and hemodialysis access, can also harbor infections that threaten vascular integrity or seed distant sites. See mycotic aneurysm for a vascular infection that produces aneurysmal dilation, and see prosthetic vascular graft for infections involving implanted grafts.

Etiology and pathophysiology

  • Native vessel infections: Infections of native arteries or veins are less common than graft-related infections but can occur from hematogenous seeding during bacteremia, contiguous infection from adjacent structures, or septic emboli. Organisms commonly implicated include Staphylococcus aureus, other staphylococci, Streptococcus species, and less often Gram-negative bacteria. The resulting tissue destruction can lead to abscess, pseudoaneurysm, or mycotic aneurysm.
  • Prosthetic vascular graft infections: Prosthetic material is particularly susceptible to infection due to biofilm formation, which impedes antibiotic penetration and host immune clearance. Early graft infections typically present within weeks of surgery and may reflect intraoperative contamination or hematogenous seeding; late infections may arise from distant bacteremia. Microbial spectra often include Staphylococcus aureus, coagulase-negative staphylococci, enteric Gram-negative rods, and mixed flora; fungal infections, though less common, can complicate immunosuppressed hosts.
  • Device-related infections: Central venous catheters, peripheral access devices, and hemodialysis grafts are frequent sources of bacteremia and catheter-related infection. These infections can seed the vascular wall or grafts and precipitate limb-threatening ischemia or systemic sepsis if not controlled.

Clinical presentation

Patients may present with fever, malaise, and leukocytosis, but the clinical picture can be dominated by local signs such as pain, warmth, or erythema over a graft site, new limb swelling, signs of limb ischemia, or pulsatile mass in the abdomen or chest. In prosthetic graft infections, patients may have tenderness, unexplained fever, wound drainage, or an elevated inflammatory response. Sepsis or septic shock can occur when bacteremia seeds distant vascular sites or when a fast-degrading infection compromises circulation. In catheter-related infections, bacteremia with a plausible catheter source is common, and removal of the catheter often becomes part of the management plan.

Diagnosis

  • Microbiology: Blood cultures are foundational. Targeted cultures from any accessible purulent collections or prosthetic material help define the organism and guide therapy. See bacteremia for a broader discussion of bloodstream infection.
  • Imaging: Cross-sectional imaging is central. CT angiography (CTA) or MR angiography can delineate the extent of infection, graft involvement, and pseudoaneurysm formation. Nuclear imaging and metabolic imaging, such as PET-CT, can be particularly helpful in prosthetic vascular graft infections when conventional imaging is inconclusive.
  • Laboratory tests: Inflammatory markers (e.g., C-reactive protein, erythrocyte sedimentation rate) are useful for monitoring response but are not specific. Serial blood cultures help document clearance of bacteremia.
  • Source assessment: Assessing for additional infectious foci and ruling out ongoing contamination of indwelling devices is essential. See central venous catheter for device-related infection considerations.

Management

A vascular infection typically requires a combination of antimicrobial therapy and source control. Management decisions are guided by the site of infection, extent of involvement, organisms, patient comorbidity, and surgical risk.

  • Antimicrobial therapy
    • Immediate empiric therapy: For suspected graft or endovascular infection, broad-spectrum IV antibiotics are started to cover likely pathogens, including Gram-positive cocci and Gram-negative rods, with adjustment once cultures are available. See antibiotic and antibiotic stewardship for Principles of appropriate antimicrobial use.
    • Targeted therapy: Narrowing to organism-specific therapy after cultures improves outcomes and reduces resistance risk. Duration is often extended in vascular infections, commonly ranging from 4 to 6 weeks after adequate source control, though longer courses may be necessary in the presence of persistent prosthetic material or uncontrolled infection.
    • Suppressive therapy: In patients who are poor surgical candidates, long-term suppressive antimicrobial therapy may be considered to mitigate risk, though this approach has limitations and requires careful discussion of risks and benefits.
  • Source control
    • Graft and tissue debridement: Removal or replacement of infected prosthetic material is frequently required for durable clearance. See prosthetic vascular graft for material-specific issues and reconstruction options.
    • In situ vs extra-anatomic bypass: After graft removal, reconstructions may be performed in place with new grafts, autologous vein, or antibiotic-impregnated/protective materials, or alternative extra-anatomic routes may be chosen to reduce reinfection risk.
    • Catheter and device management: Removal or exchange of infected catheters or other devices is a critical step when they are identified as the source.
  • Surgical and endovascular approaches
    • Endovascular strategies can be temporizing or definitive in select cases, particularly in high-risk patients, with plans for eventual definitive management. See endovascular surgery for broader context.
    • Early surgical intervention generally improves outcomes when feasible, though decisions must balance operative risk against the severity of infection and patient comorbidity.
  • Prevention and rehabilitation
    • Prophylaxis in vascular procedures: Preoperative and perioperative antibiotic prophylaxis remains a cornerstone of reducing infection risk in vascular surgery. See preoperative antibiotic prophylaxis for related standards.
    • Device care and line management: Meticulous care of invasive lines and devices reduces infection risk. See central venous catheter for device-related considerations.
    • Rehabilitation and follow-up: Monitoring for relapse or persistent infection is essential, with periodic imaging and laboratory assessment guided by the clinical course.

Prevention, policy considerations, and debates

Preventing vascular infections hinges on surgical technique, appropriate use of prophylaxis, and prudent device management. From a pragmatic, market-informed perspective, efficient care pathways emphasize timely diagnosis, rapid source control, and effective antimicrobial stewardship to maximize outcomes while controlling costs. Advocates point to the importance of ensuring access to high-quality vascular surgery, imaging, and infectious disease support, arguing that overregulation or excessive bureaucratic hurdles can delay life-preserving treatment. Conversely, critics warn that without disciplined antibiotic stewardship and evidence-based protocols, broad-spectrum antibiotic use and expensive diagnostics can drive unnecessary costs and foster resistance.

Controversies in this arena often touch on the balance between aggressive surgical management and conservative approaches in high-risk patients, the optimal duration of antibiotic therapy after source control, and the role of advanced imaging modalities such as PET-CT in routine practice. Proponents of streamlined care argue that early, decisive intervention yields better survival and limb preservation, while proponents of cautious resource use emphasize patient safety, cost containment, and avoiding overtreatment. In discussing equity and access to care, some debates focus on how to ensure timely access to specialized vascular services without creating disincentives for innovation or clinical autonomy; others critique policy measures that they perceive as delaying care or prioritizing abstract metrics over concrete clinical needs. See antibiotic stewardship and preoperative antibiotic prophylaxis for standards that aim to harmonize effectiveness with prudent resource use.

As with many areas of medicine, there is ongoing discussion about the role of evolving technologies and procedures. For example, the use of antibiotic-impregnated grafts or novel reconstruction techniques can influence reinfection rates, but adoption depends on demonstrated value, surgeon expertise, and cost considerations. See prosthetic vascular graft and in situ reconstruction for more on material choices and reconstructive options. Critics cautions against overreliance on expensive diagnostics when clinical assessment and targeted cultures provide adequate direction, while supporters argue that precise imaging can prevent catastrophic outcomes by guiding timely surgery.

See also